{"product_id":"gild-vrio-analysis","title":"Gilead Sciences, Inc. (GILD): VRIO Analysis [June-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eThis ready-made VRIO Analysis of Gilead Sciences, Inc. gives you a research-based view of how the company creates value through HIV leadership, Biktarvy, long-acting prevention, oncology, Livdelzi, IP protection, AI-enabled R\u0026amp;D, manufacturing, and financial strength as of June 2026. You’ll see which resources create sustained versus temporary competitive advantage, including access across \u003cstrong\u003e120-plus countries\u003c\/strong\u003e and a \u003cstrong\u003e$32B\u003c\/strong\u003e capital plan, making it a practical study aid for essays, case studies, presentations, and business analysis.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eGilead Sciences, Inc. - VRIO Analysis: First Core Capabilities \/ Resources: HIV franchise and Biktarvy brand leadership\n\u003c\/h2\u003e\n\u003cp\u003eGilead Sciences' HIV franchise generated \u003cstrong\u003e$19.6B\u003c\/strong\u003e in 2024 product sales, and Biktarvy generated \u003cstrong\u003e$13.4B\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO factor\u003c\/th\u003e\n\u003cth\u003eNumber\u003c\/th\u003e\n\u003cth\u003eWhat it shows\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$19.6B\u003c\/strong\u003e HIV product sales; \u003cstrong\u003e$13.4B\u003c\/strong\u003e Biktarvy sales\u003c\/td\u003e\n\u003ctd\u003eBiktarvy produced \u003cstrong\u003e68.6%\u003c\/strong\u003e of HIV product sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e68.6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOne brand at this scale is uncommon in biopharma\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2018-2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e7\u003c\/strong\u003e years of scale building\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13.4B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCommercial execution supported continued large-scale sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive advantage\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13.4B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSustained\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eBiktarvy drove \u003cstrong\u003e$13.4B\u003c\/strong\u003e of 2024 sales inside a \u003cstrong\u003e$19.6B\u003c\/strong\u003e HIV franchise.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eBiktarvy accounted for \u003cstrong\u003e68.6%\u003c\/strong\u003e of HIV product sales in 2024.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eThe commercial base was built over \u003cstrong\u003e7\u003c\/strong\u003e years, from \u003cstrong\u003e2018\u003c\/strong\u003e to \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eGilead Sciences kept Biktarvy at \u003cstrong\u003e$13.4B\u003c\/strong\u003e through 2024 execution.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eThe combination of \u003cstrong\u003e$19.6B\u003c\/strong\u003e HIV sales and \u003cstrong\u003e$13.4B\u003c\/strong\u003e Biktarvy sales supports a sustained advantage.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$19.6B\u003c\/strong\u003e HIV product sales\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$13.4B\u003c\/strong\u003e Biktarvy sales\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e68.6%\u003c\/strong\u003e of HIV product sales from Biktarvy\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2018-2024\u003c\/strong\u003e commercial scale build\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eGilead Sciences, Inc. - VRIO Analysis: Second Core Capabilities \/ Resources: Long-acting HIV prevention and treatment platform\u003c\/h2\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eThe platform adds a \u003cstrong\u003e6\u003c\/strong\u003e-month dosing option and sits inside an HIV franchise that generated \u003cstrong\u003e$19.6 billion\u003c\/strong\u003e in product sales in \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eThis is rare because the U.S. has a \u003cstrong\u003efirst\u003c\/strong\u003e twice-yearly injectable PrEP option, with FDA approval on \u003cstrong\u003eJune 18, 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eIt is hard to copy because it rests on \u003cstrong\u003e2\u003c\/strong\u003e lenacapavir approvals, plus long-acting formulation and regulatory know-how built over multiple years.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eGilead is organized for this with a \u003cstrong\u003e2\u003c\/strong\u003e-indication lenacapavir platform and an HIV commercial base large enough to support launch and scale.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eVRIO factor\u003c\/th\u003e\n    \u003cth\u003eReal-life data point\u003c\/th\u003e\n    \u003cth\u003eAssessment\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e6\u003c\/strong\u003e-month dosing; \u003cstrong\u003e$19.6 billion\u003c\/strong\u003e HIV product sales in \u003cstrong\u003e2024\u003c\/strong\u003e\n\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003eFirst twice-yearly injectable PrEP option; FDA approval on \u003cstrong\u003eJune 18, 2025\u003c\/strong\u003e\n\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eImitability\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e approvals and long-acting formulation and regulatory know-how\u003c\/td\u003e\n    \u003ctd\u003eDifficult\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e lenacapavir indications and HIV commercial infrastructure\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCompetitive advantage\u003c\/td\u003e\n    \u003ctd\u003eSustained\u003c\/td\u003e\n    \u003ctd\u003eSustained\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e2024:\u003c\/strong\u003e HIV product sales of \u003cstrong\u003e$19.6 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e2025:\u003c\/strong\u003e FDA approval for the first twice-yearly injectable PrEP option\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e6\u003c\/strong\u003e-month dosing interval\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e lenacapavir indications\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eGilead Sciences, Inc. - VRIO Analysis: Third Core Capabilities \/ Resources: Oncology development and commercialization engine\u003c\/h2\u003e\n\u003cp\u003eOncology is a \u003cstrong\u003etemporary\u003c\/strong\u003e VRIO advantage for Gilead because it combines a \u003cstrong\u003e$21 billion\u003c\/strong\u003e ADC acquisition, a \u003cstrong\u003e$11.9 billion\u003c\/strong\u003e cell therapy acquisition, and multiple FDA approvals dated \u003cstrong\u003eApril 22, 2020\u003c\/strong\u003e, \u003cstrong\u003eApril 13, 2021\u003c\/strong\u003e, and \u003cstrong\u003eFebruary 3, 2023\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$21 billion\u003c\/strong\u003e Immunomedics acquisition in \u003cstrong\u003e2020\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$11.9 billion\u003c\/strong\u003e Kite acquisition in \u003cstrong\u003e2017\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e commercial cell therapy products: Yescarta and Tecartus\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e sacituzumab govitecan FDA approval dates: \u003cstrong\u003eApril 22, 2020\u003c\/strong\u003e, \u003cstrong\u003eApril 13, 2021\u003c\/strong\u003e, \u003cstrong\u003eFebruary 3, 2023\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO factor\u003c\/th\u003e\n\u003cth\u003eReal-life data\u003c\/th\u003e\n\u003cth\u003eAnalytical effect\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$21 billion\u003c\/strong\u003e and \u003cstrong\u003e$11.9 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eDiversifies revenue beyond HIV\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e commercial cell therapy products plus an ADC franchise\u003c\/td\u003e\n\u003ctd\u003eFew peers have this mix at scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e approval dates across \u003cstrong\u003e2020\u003c\/strong\u003e, \u003cstrong\u003e2021\u003c\/strong\u003e, and \u003cstrong\u003e2023\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eHard to copy quickly\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eClinical, regulatory, and partnering functions\u003c\/td\u003e\n\u003ctd\u003eSupports execution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eThe oncology engine adds non-HIV growth through sacituzumab govitecan and multiple combination-development programs, supported by the \u003cstrong\u003e$21 billion\u003c\/strong\u003e Immunomedics deal and the \u003cstrong\u003e$11.9 billion\u003c\/strong\u003e Kite deal.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eThe mix of an ADC asset and \u003cstrong\u003e2\u003c\/strong\u003e marketed cell therapies is uncommon among large biopharma companies.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eCompetitors can build similar assets, but not quickly, because the market entry path runs through multibillion-dollar M\u0026amp;A and multi-year clinical work.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eGilead has integrated oncology clinical, regulatory, and partnering functions in place across development and commercialization.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eTemporary\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eGilead Sciences, Inc. - VRIO Analysis: Fourth Core Capabilities \/ Resources: Inflammation and liver disease franchise via Livdelzi\n\u003c\/h2\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e$4.3 billion\u003c\/strong\u003e and \u003cstrong\u003eAugust 14, 2024\u003c\/strong\u003e created a new specialty liver platform in PBC.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e1\u003c\/strong\u003e approved PPAR-delta agonist for PBC in the U.S. gives Gilead a niche position.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eReplicating a \u003cstrong\u003e$4.3 billion\u003c\/strong\u003e acquisition plus a \u003cstrong\u003e1\u003c\/strong\u003e-product rare-disease launch is hard, but not permanent.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eGilead has already shown acquisition integration and commercial launch capability in \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO element\u003c\/td\u003e\n\u003ctd\u003eReal-life number\/date\u003c\/td\u003e\n\u003ctd\u003eFact\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.3 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCymaBay Therapeutics acquisition value\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eAugust 14, 2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFDA approval date for Livdelzi in PBC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eApproved PPAR-delta agonist for PBC in the U.S.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSpecialty rare-liver-disease franchise with one approved asset\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAcquisition integration and commercial rollout year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003e$4.3 billion\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eAugust 14, 2024\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e1\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e2024\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eTemporary\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eGilead Sciences, Inc. - VRIO Analysis: Fifth Core Capabilities \/ Resources: Intellectual property estate and legal-regulatory expertise\u003c\/h2\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e$27.1 billion\u003c\/strong\u003e in 2023 revenue, plus IP-heavy deals worth \u003cstrong\u003e$11.2 billion\u003c\/strong\u003e in 2011, \u003cstrong\u003e$11.9 billion\u003c\/strong\u003e in 2017, and up to \u003cstrong\u003e$21.0 billion\u003c\/strong\u003e in 2020, shows direct cash value from exclusivity, pricing power, and monetization.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eThe mix of patent assets, licensing reach, and dispute execution is uncommon: a license covering \u003cstrong\u003e91\u003c\/strong\u003e countries with \u003cstrong\u003e11\u003c\/strong\u003e generic manufacturers, plus a \u003cstrong\u003e$2.54 billion\u003c\/strong\u003e Merck patent settlement in 2017.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eVRIO test\u003c\/th\u003e\n    \u003cth\u003eReal-life number\u003c\/th\u003e\n    \u003cth\u003eWhy it matters\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e$27.1 billion\u003c\/strong\u003e revenue in 2023\u003c\/td\u003e\n    \u003ctd\u003eShows monetization from protected products\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e91\u003c\/strong\u003e countries, \u003cstrong\u003e11\u003c\/strong\u003e generic manufacturers\u003c\/td\u003e\n    \u003ctd\u003eRare licensing reach with legal control\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eImitability\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e2011\u003c\/strong\u003e, \u003cstrong\u003e2017\u003c\/strong\u003e, \u003cstrong\u003e2020\u003c\/strong\u003e deal years; \u003cstrong\u003e$2.54 billion\u003c\/strong\u003e settlement\u003c\/td\u003e\n    \u003ctd\u003eBuilt over time, not copied quickly\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e$11.2 billion\u003c\/strong\u003e, \u003cstrong\u003e$11.9 billion\u003c\/strong\u003e, \u003cstrong\u003e$21.0 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n    \u003ctd\u003eShows capital and regulatory execution capacity\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eHard to copy because the position was assembled over \u003cstrong\u003e2011\u003c\/strong\u003e, \u003cstrong\u003e2017\u003c\/strong\u003e, and \u003cstrong\u003e2020\u003c\/strong\u003e, and reinforced by a \u003cstrong\u003e$2.54 billion\u003c\/strong\u003e settlement record that newer rivals do not have.\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e$11.2 billion\u003c\/strong\u003e Pharmasset acquisition in \u003cstrong\u003e2011\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e$11.9 billion\u003c\/strong\u003e Kite Pharma acquisition in \u003cstrong\u003e2017\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eUp to \u003cstrong\u003e$21.0 billion\u003c\/strong\u003e Immunomedics acquisition in \u003cstrong\u003e2020\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e$2.54 billion\u003c\/strong\u003e Merck patent settlement in \u003cstrong\u003e2017\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e91\u003c\/strong\u003e countries and \u003cstrong\u003e11\u003c\/strong\u003e generic manufacturers in the license structure\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eGilead Sciences, Inc. has shown the legal, compliance, and regulatory capacity to convert IP into enforceable economics through transactions of \u003cstrong\u003e$11.2 billion\u003c\/strong\u003e, \u003cstrong\u003e$11.9 billion\u003c\/strong\u003e, and \u003cstrong\u003e$21.0 billion\u003c\/strong\u003e, plus a \u003cstrong\u003e$2.54 billion\u003c\/strong\u003e settlement.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eSustained\u003c\/strong\u003e through \u003cstrong\u003e$27.1 billion\u003c\/strong\u003e revenue, \u003cstrong\u003e91\u003c\/strong\u003e-country licensing reach, and \u003cstrong\u003e$2.54 billion\u003c\/strong\u003e litigation leverage.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eGilead Sciences, Inc. - VRIO Analysis: Sixth Core Capabilities \/ Resources: Global commercialization and access network\n\u003c\/h2\u003e\n\u003cp\u003eGilead Sciences, Inc.'s access network reaches \u003cstrong\u003e120\u003c\/strong\u003e countries through \u003cstrong\u003e6\u003c\/strong\u003e generic manufacturers, which makes the resource valuable and difficult to copy quickly.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO item\u003c\/th\u003e\n\u003cth\u003eReal-life number\u003c\/th\u003e\n\u003cth\u003eAnalysis link\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLenacapavir voluntary license coverage\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e120\u003c\/strong\u003e countries\u003c\/td\u003e\n\u003ctd\u003eValue, rarity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneric manufacturers in the access structure\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eImitability barrier\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eCoverage across \u003cstrong\u003e120\u003c\/strong\u003e countries extends patient reach and market access beyond direct commercial sales.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eA broad HIV access structure tied to \u003cstrong\u003e120\u003c\/strong\u003e countries is rare.\u003c\/p\u003e\n\n\u003ch3\u003eInimitability\u003c\/h3\u003e\n\u003cp\u003eReplicating a network built around \u003cstrong\u003e120\u003c\/strong\u003e countries and \u003cstrong\u003e6\u003c\/strong\u003e generic manufacturers needs country-by-country relationships and infrastructure.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e120\u003c\/strong\u003e countries\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e6\u003c\/strong\u003e generic manufacturers\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eGilead Sciences, Inc. - VRIO Analysis: Seventh Core Capabilities \/ Resources: AI-enabled R\u0026amp;D and drug discovery engine\u003c\/h2\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eGilead’s AI-linked discovery effort is tied to a \u003cstrong\u003e$32B\u003c\/strong\u003e capital plan and a \u003cstrong\u003e2024\u003c\/strong\u003e Genesis collaboration, which supports faster target identification, molecule design, and pipeline screening.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eAt Gilead’s scale, pairing a \u003cstrong\u003e$32B\u003c\/strong\u003e capital plan with external AI discovery partnerships is uncommon.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eIt is hard to copy without comparable data, scientific talent, compute capacity, and wet-lab integration across the R\u0026amp;D stack.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eGilead appears organized to use this capability through the Genesis collaboration, a new technical center, and the \u003cstrong\u003e$32B\u003c\/strong\u003e capital plan.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO test\u003c\/th\u003e\n\u003cth\u003eReal-life data point\u003c\/th\u003e\n\u003cth\u003eEffect\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$32B\u003c\/strong\u003e; \u003cstrong\u003e2024\u003c\/strong\u003e; Genesis collaboration\u003c\/td\u003e\n\u003ctd\u003eSupports R\u0026amp;D productivity and risk reduction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$32B\u003c\/strong\u003e; Genesis collaboration\u003c\/td\u003e\n\u003ctd\u003eLess common at large pharma scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eData, talent, compute, wet-lab integration\u003c\/td\u003e\n\u003ctd\u003eHard to duplicate quickly\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eNew technical center; Genesis collaboration; \u003cstrong\u003e$32B\u003c\/strong\u003e capital plan\u003c\/td\u003e\n\u003ctd\u003eShows execution capacity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive advantage\u003c\/td\u003e\n\u003ctd\u003eSustained\u003c\/td\u003e\n\u003ctd\u003eDurable if investment and partnerships continue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$32B\u003c\/strong\u003e capital plan supports continued investment.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e Genesis collaboration adds external AI capability.\u003c\/li\u003e\n\u003cli\u003eNew technical center supports internal execution.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eGilead Sciences, Inc. - VRIO Analysis: Eighth Core Capabilities \/ Resources: Manufacturing and technical development infrastructure\u003c\/h2\u003e\n\u003cp\u003eGilead's manufacturing and technical development infrastructure is a sustained advantage because it supports \u003cstrong\u003e2\u003c\/strong\u003e marketed CAR-T therapies and was built through large transactions, including \u003cstrong\u003e$11.9 billion\u003c\/strong\u003e in \u003cstrong\u003e2017\u003c\/strong\u003e, \u003cstrong\u003e$21.0 billion\u003c\/strong\u003e in \u003cstrong\u003e2020\u003c\/strong\u003e, and \u003cstrong\u003e$4.3 billion\u003c\/strong\u003e in \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eThis resource improves supply reliability, quality control, launch readiness, and cost efficiency for complex therapies that depend on validated production and technical transfer.\u003c\/p\u003e\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eMetric\u003c\/td\u003e\n    \u003ctd\u003eReal-life data\u003c\/td\u003e\n    \u003ctd\u003eVRIO effect\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eFounded\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e1987\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eLong operating history supports process know-how\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eKite Pharma acquisition\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e$11.9 billion\u003c\/strong\u003e in \u003cstrong\u003e2017\u003c\/strong\u003e\n\u003c\/td\u003e\n    \u003ctd\u003eAdded cell therapy manufacturing depth\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eImmunomedics acquisition\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e$21.0 billion\u003c\/strong\u003e in \u003cstrong\u003e2020\u003c\/strong\u003e\n\u003c\/td\u003e\n    \u003ctd\u003eExpanded oncology technical development\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCymaBay acquisition\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e$4.3 billion\u003c\/strong\u003e in \u003cstrong\u003e2024\u003c\/strong\u003e\n\u003c\/td\u003e\n    \u003ctd\u003eAdded late-stage development capability\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eMarketed CAR-T therapies\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eShows commercial use of the infrastructure\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eLarge-scale, compliant biopharma manufacturing capacity is difficult to assemble, and Gilead's \u003cstrong\u003e2\u003c\/strong\u003e marketed CAR-T therapies show a narrower capability set than most large drugmakers.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eIt is hard to imitate because the capability requires capital intensity, regulatory standards, and years of operational experience, reflected in acquisitions of \u003cstrong\u003e$11.9 billion\u003c\/strong\u003e, \u003cstrong\u003e$21.0 billion\u003c\/strong\u003e, and \u003cstrong\u003e$4.3 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cul class=\"lst_crct\"\u003e\n  \u003cli\u003e\n\u003cstrong\u003e2017\u003c\/strong\u003e: Kite Pharma acquisition for \u003cstrong\u003e$11.9 billion\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e2020\u003c\/strong\u003e: Immunomedics acquisition for \u003cstrong\u003e$21.0 billion\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e: CymaBay acquisition for \u003cstrong\u003e$4.3 billion\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e marketed CAR-T therapies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eGilead has organized capital and development around these assets through U.S. investment, technical development expansion, and global operations.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eGilead Sciences, Inc. - VRIO Analysis: Ninth Core Capabilities \/ Resources: Financial strength and capital allocation capacity\n\u003c\/h2\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO item\u003c\/th\u003e\n\u003cth\u003eReal-life number\u003c\/th\u003e\n\u003cth\u003eYear\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet cash provided by operating activities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.2 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQuarterly dividend\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$0.77\u003c\/strong\u003e per share\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnualized dividend\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$3.08\u003c\/strong\u003e per share\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImmunomedics acquisition\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$21.0 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2020\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSenior notes issuance\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$9.5 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2020\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCymaBay acquisition\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.3 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e$10.2 billion\u003c\/strong\u003e; \u003cstrong\u003e$3.08\u003c\/strong\u003e; \u003cstrong\u003e$21.0 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e$10.2 billion\u003c\/strong\u003e; not rare among large pharma.\u003c\/p\u003e\n\u003ch3\u003eInimitability\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e$9.5 billion\u003c\/strong\u003e; \u003cstrong\u003e$4.3 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch3\u003eOrganized\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e$21.0 billion\u003c\/strong\u003e; \u003cstrong\u003e$9.5 billion\u003c\/strong\u003e; \u003cstrong\u003e$4.3 billion\u003c\/strong\u003e; \u003cstrong\u003e$0.77\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eTemporary.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516172787861,"sku":"gild-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/gild-vrio-analysis.png?v=1740177785","url":"https:\/\/dcf-model.com\/fr\/products\/gild-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}